NAUT

$2.66+0.27 (+11.44%)

Market OpenAs of Mar 17, 7:05 PM UTC

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.66
Potential Upside
5%
Whystock Fair Value$2.80
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, whic...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$337.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-32.27%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
13.00

Recent News

Moby
Feb 27, 2026

Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary

Moby summary of Nautilus Biotechnology, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 26, 2026

Nautilus Biotechnology Q4 Earnings Call Highlights

Nautilus Biotechnology (NASDAQ:NAUT) used its fourth-quarter 2025 earnings call to highlight recent steps toward commercialization of its proteomics platform, alongside continued cost reductions and updated expectations for 2026 spending and revenue. Management said 2025 closed with “tangible progre

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 26, 2026

Nautilus Biotechnology Inc (NAUT) Q4 2025 Earnings Call Highlights: Strategic Advances and ...

Nautilus Biotechnology Inc (NAUT) reports a significant decrease in operating expenses and unveils promising collaborations, while preparing for increased investment in 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Feb 22, 2026

Jefferies Upgrades BETA Technologies, Inc. (BETA) to Buy

BETA Technologies, Inc. (NYSE:BETA) is among the 11 Newly-Listed NYSE Stocks to Buy Now. On February 11, 2026, Jefferies analyst Sheila Kahyaoglu upgraded BETA Technologies, Inc. (NYSE:BETA) to Buy from Hold, previously with a $30 price target. Sheila Kahyaoglu said the shares look compelling at current levels following recent risk-off trading and ahead of several […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 6, 2026

3 Penny Stocks With Market Caps Over $50M To Watch

As February begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. This optimistic start to the month highlights a market environment where investors are keenly exploring opportunities across various sectors. Though often seen as a relic of past trading days, penny stocks still represent significant growth potential, particularly when they come from smaller or newer companies with strong financial foundations.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.